Influence of a systemically administered aromatic retinoid (Ro 10-9359) on the light sensitivity.
The light sensitivity was determined on 14 psoriasis patients using two different light sources before, and after a three week period of systemic administration of 75 to 100 mg daily of the aromatic retinoid (ethyl ester of all-trans-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid, Ro 10-9359 [1]). The results indicate that with this therapy, the light sensitivity remains unchanged or even decreases; there is thus no contraindication to the simultaneous application of phototherapy and the systemic administration of this retinoic acid derivative.
D000284:Administration, Oral; D005050:Etretinate / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D010787:Photosensitivity Disorders / Q000209:etiology / Q000517:prevention & control*; D010789:Phototherapy; D011565:Psoriasis / Q000150:complications / Q000628:therapy*; D014212:Tretinoin / Q000031:analogs & derivatives*; D014467:Ultraviolet Therapy
D014212:Tretinoin; D005050:Etretinate